Cells develop resistance to venetoclax through various other mechanisms, such as BAX mutations, RNA methylation, antiapoptotic pathways other than those mediated by the BCL-2 family, tumor suppressor mutations, and abnormal cell cycle regulation. The gene discussed is BCL2; the disease is neoplasm.